Search results for "Pollen"

showing 10 items of 302 documents

Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma.

2012

The role of IgE in patients with severe asthma is not fully understood.We sought to investigate whether IgE to Staphylococcus aureus enterotoxins might be relevant to disease severity in adult asthmatic patients.Specific IgE antibody concentrations in serum against enterotoxins, grass pollen (GP), and house dust mite allergens and total IgE levels were measured in adult cohorts of 69 control subjects, 152 patients with nonsevere asthma, and 166 patients with severe asthma. Severe asthma was defined as inadequately controlled disease despite high-dose inhaled corticosteroids plus at least 2 other controller therapies, including oral steroids.Enterotoxin IgE positivity was significantly great…

AdultMaleStaphylococcus aureusImmunologymacromolecular substancesEnterotoxinImmunoglobulin EStaphylococcal infectionsAnti-asthmatic AgentSeverity of Illness IndexFEV1Enterotoxinsimmune system diseasesAdrenal Cortex HormonesRisk FactorsmedicineImmunology and AllergyAnimalsHumansAnti-Asthmatic AgentshospitalizationsAsthmaHouse dust miteEosinophil cationic proteinSuperantigensbiologybusiness.industryasthma severityPyroglyphidaeAtopic dermatitisAllergensImmunoglobulin EMiddle AgedStaphylococcal Infectionsmedicine.diseasebiology.organism_classificationAntibodies BacterialAsthmarespiratory tract diseasesCase-Control StudiesImmunologybiology.proteinPollenFemaleIgEbusinessThe Journal of allergy and clinical immunology
researchProduct

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbi…

2008

Summary Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. Objective The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. Methods A randomized, double-blind, placebo-controlled, multi-centre trial was performed to assess the efficacy and safety of omalizumab (Xolair®) vs. placebo in combination with depigmented SIT (Depigoid®) during the grass pollen season. Omalizumab or placebo was started 2 weeks befor…

AdultMalemedicine.medical_specialtyAdolescentCombination therapyImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedPlacebolaw.inventionYoung AdultPharmacotherapyDouble-Blind MethodRandomized controlled triallawForced Expiratory VolumeInternal medicineAnti-Allergic AgentsmedicineClinical endpointHumansImmunology and AllergyChildConjunctivitis AllergicAsthmaPlant Extractsbusiness.industryAntibodies MonoclonalRhinitis Allergic SeasonalAntigens PlantMiddle Agedmedicine.diseaseCombined Modality TherapyAsthmaAntibodies Anti-IdiotypicRespiratory Function TestsTreatment OutcomeDesensitization ImmunologicAsthma Control QuestionnaireQuality of LifePhysical therapyPollenFemalebusinessmedicine.drugClinical & Experimental Allergy
researchProduct

Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens.

1998

The efficacy and tolerance of short-term immunotherapy (STI) by seven preseasonal injections of tree-pollen allergens (ALK7 Fruhbluhermischung) was investigated in a double-blind, placebo-controlled, multicenter study with 111 rhinoconjunctivitis patients. Nasal and bronchial symptoms simultaneously analyzed, and nasal symptoms as a single end point, but not the overall score of nasal, bronchial, and conjunctival symptoms, showed a significantly lower increase with STI during birch-pollen exposure (both P=0.033, n=105, Mann-Whitney U-test). However, a selective analysis with patients from centers with high recruitment figures (n> or =10 patients, n=29 STI, n=32 placebo) showed a significant…

AdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentmedicine.medical_treatmentImmunologyPlaceboImmunoglobulin Emedicine.disease_causeGastroenterologyInjectionsTreesAllergenRibonucleasesDouble-Blind MethodInternal medicineImmunopathologyotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansDesensitization (medicine)Conjunctivitis AllergicSkin TestsEosinophil cationic proteinbiologybusiness.industryRhinitis Allergic SeasonalBlood Proteinsrespiratory systemAllergensEosinophil Granule ProteinsImmunoglobulin EMiddle Agedmedicine.diseaseClinical trialTreatment OutcomeDesensitization ImmunologicImmunoglobulin GImmunologybiology.proteinPollenFemalebusinessAllergy
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

Multi-model ensemble simulations of olive pollen distribution in Europe in 2014: current status and outlook

2017

"Çalışmada 29 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır” The paper presents the first modelling experiment of the European-scale olive pollen dispersion, analyses the quality of the predictions, and outlines the research needs. A 6-model strong ensemble of Copernicus Atmospheric Monitoring Service (CAMS) was run throughout the olive season of 2014, computing the olive pollen distribution. The simulations have been compared with observations in eight countries, which are members of the European Aeroallergen Network (EAN). Analysis was performed for individual models, the ensemble mean and median, and for a dynamically optimised c…

Allergenic pollenAtmospheric Science010504 meteorology & atmospheric sciencesAirborne pollenEnsemble averagingDistribution (economics)olive pollen airborne pollen modeling pollen forecasting multi-ensemble data fusion aerobiologyAtmospheric model010501 environmental sciences01 natural scienceslcsh:Chemistryddc:550Ragweed; Ambrosia Artemisiifolia; PollenMathematicsDry deposition schemeLand-surface parametersBerian peninsulaEnsemble forecastingDispersionAdvection algorithmiMiljövetenskaplcsh:QC1-999EuropeAtmospheric modelingClimatologyPollenEnvironment & SustainabilityBirch pollenGlobal databaseUrbanisationEnvironmentConsistency (statistics)Environmental sciences & ecologyStatistical dispersionddc:610PrecipitationOlea-europaea0105 earth and related environmental sciencesEnsemble forecastingbusiness.industryResearchCAS - Climate Air and SustainabilityWeightingEnvironmental sciences2015 Urban Mobility & Environmentlcsh:QD1-999Meteorology & atmospheric sciencesEuropean-scale olive pollen dispersion ; European Aeroallergen Network (EAN)Long-range transportELSS - Earth Life and Social SciencesPredictionbusinessEnvironmental Scienceslcsh:PhysicsAtmospheric Chemistry and Physics
researchProduct

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

2015

Accepted Article

AllergyAllergyMedical InformaticSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOWORLD-HEALTH-ORGANIZATIONReviewComorbidityWeb BrowserHealth informatics:Medicina Clínica [Ciências Médicas]ARIA; ICT; MACVIA-LR; allergic rhinitis; asthma; clinical decision support system; conjunctivitis; visual analogue scalevisual analogue scaleQUALITY-OF-LIFEconjunctivitisMedicineImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSRhinitisClinical Trials as TopicCLIMATE-CHANGE[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAllergenHealth PolicyDisease ManagementRANDOMIZED CONTROLLED-TRIAL3. Good healthCHRONIC RESPIRATORY-DISEASESclinical decision support systemINTEGRATED CARE PATHWAYS1107 ImmunologyVISUAL ANALOG SCALESPractice Guidelines as TopicMedical emergencyallergic rhinitiLife Sciences & BiomedicineHumanEUROPEAN INNOVATION PARTNERSHIPImmunologyClinical Decision-MakingSocio-culturaleReproducibility of Resultallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web Browser; Immunology and Allergy; ImmunologyInformation and communications technologyClinical decision support systemMACVIA-LRQuality of life (healthcare)AllergicARIA; Information and communications technology; MACVIA-LR; allergic rhinitis; asthmaJournal ArticleHumansCiências Médicas::Medicina ClínicaAsthmaScience & Technologyallergic rhinitisARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAReproducibility of ResultsGuidelineBiomarkerta3121Allergensasthmamedicine.diseaseRhinitis AllergicIntegrated careHealth PlanningPOLLEN COUNTSICTallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web BrowserImmunologybusinessDECISION-SUPPORT-SYSTEMSBiomarkersMedical Informatics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product f…

2012

Background Subcutaneous specific immunotherapy (SCIT) has proven sustained clinical efficacy against allergy. The recommended regimen for SCIT is a gradual updosing over a period of weeks. Commonly, in commercial products for SCIT, the specific allergen is formulated with an adjuvant, most often in the form of aluminium hydroxide (AlOH). It has been shown that allergen-specific IgG antibodies are induced as a result of successful SIT. Objective To investigate the possibility of optimizing the formulation of AlOH-based grass-pollen allergy vaccines for SCIT in a way that allows for shorter updosing regimens while maintaining the immunogenicity of the vaccine. Methods Mice were immunized with…

AllergyInjections SubcutaneousT-LymphocytesT cellmedicine.medical_treatmentImmunologyAluminum HydroxidePharmacologyPoaceaemedicine.disease_causePhleumMiceAllergenAdjuvants ImmunologicAnimalsHumansImmunology and AllergyMedicineMice Inbred BALB CbiologyPlant Extractsbusiness.industryImmunogenicityRhinitis Allergic SeasonalAllergen extractAllergensmedicine.diseasebiology.organism_classificationTreatment Outcomemedicine.anatomical_structureDesensitization ImmunologicImmunoglobulin GPhleumImmunologybiology.proteinPollenFemaleAntibodybusinessAdjuvantClinical & Experimental Allergy
researchProduct

Effects of Parietaria judaica pollen extract on human microvascular endothelial cells

2008

Abstract Pollinosis from Parietaria judaica is one of the main causes of allergy in the Mediterranean area. The present study is designed to assess if P. judaica pollens contain bioactive compounds able to elicit a functional response in endothelial cells. We have demonstrated that addition of pollen extract to human lung microvascular endothelial cells (HMVEC-L) induces a modification of cell morphology, actin cytoskeletal rearrangements and an increase in endothelial cell permeability. We further showed that the treatment of endothelial cells with pollen extract causes an increase of E-selectin and VCAM-1 protein levels as well as an increase of IL-8 production. The stimulation of cell–ce…

AllergyNeutrophilsBiophysicsVascular Cell Adhesion Molecule-1parietaria judaicaBiologymedicine.disease_causeCell morphologyBiochemistryPermeabilitycell adhesion moleculesPollenCell AdhesionmedicineHumansProtease InhibitorsCytoskeletonLungMolecular BiologyCells CulturedActinPlant ExtractsCell adhesion moleculeInterleukin-8Cell BiologyAdhesionbiology.organism_classificationCapillariesCell biologyEndothelial stem cellParietariaImmunologyParietaria judaicaendothelial cellPollenEndothelium VascularE-Selectin
researchProduct

A Hybrid Expressing Genetically Engineered Major Allergens of the <i>Parietaria</i> Pollen as a Tool for Specific Allergy Vaccination

2006

<i>Background:</i> Allergy is an immunological disorder affecting about 25% of the population living in the industrialized countries. Specific immunotherapy is the only treatment with a long-lasting relief of allergic symptoms and able to reduce the risk of developing new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis. <i>Methods:</i> By means of DNA recombinant technology, we were able to design a head to tail dimer expressing disulphide bond variants of the major allergen of the <i>Parietaria </i>pollen. IgE binding activity was studied by Western blot, ELISA inhibition assays and the …

Allergyeducation.field_of_studyParietariabiologyGenetically engineeredImmunologyPopulationSpecific immunotherapyGeneral Medicinebiology.organism_classificationmedicine.disease_causemedicine.diseaseVaccinationAllergenPollenImmunologymedicineImmunology and AllergyeducationInternational Archives of Allergy and Immunology
researchProduct

Microspore Embryogenesis in Citrus

2021

This chapter deals with microspore embryogenesis in Citrus. Microspore embryogenesis allows to induce immature gametes (microspores) and to deviate them, in this case, the male one, from the normal gametophytic developmental route in the direction of the sporophytic one, yielding homozygous organisms (embryos and plants).

Anther cultureEmbryogenesisCitrufood and beveragesEmbryonic DevelopmentEmbryoBiologyHaploidymedicine.disease_causeHomozygosityCell biologyMicrosporeGene Expression Regulation PlantPollenmedicineIsolated microspore culturePollen
researchProduct